Compare H World Group Limited American Depositary Shares (HTHT) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
H World Group Limited American Depositary Shares vs Tango Therapeutics Inc. — how do they compare? H World Group Limited American Depositary Shares trades at $44.2 (market cap $14.16B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: H World Group Limited American Depositary Shares is far larger — about 3.8× Tango Therapeutics Inc.'s market cap, and H World Group Limited American Depositary Shares pays a 4.91% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold H World Group Limited American Depositary Shares for 6 Days and Tango Therapeutics Inc. for 0 Days on average.
| HTHT | TNGX | |
|---|---|---|
Market Cap | $14.16B | $3.75B |
Volume | 1,525,108 | 9,619,106 |
Sector | Consumer Cyclical | Health |
52-Week High | $56.06 | $32.90 |
52-Week Low | $36.99 | $7.50 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $16.95B | $2.77B |
Dividend Yield | 4.91% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HTHT trades at $44.17, down 0.85% on the day, with a bullish technical signal supported by moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $0.78 exceeding the $0.74 estimate. Revenue for 2025 was $25.31 billion, with a net income margin of 18.93% and robust ROE of 38.39%. Positive news highlights the asset-light model's margin improvement and a recent CNY bond offering.
The outlook remains positive with a consensus price target of $50.56, implying 14.5% upside, supported by earnings momentum and operational efficiency. Key risks include market saturation in China and reliance on domestic growth. Analyst sentiment is bullish with 11 buy ratings out of 19, though valuation multiples like a P/E of 31.46 warrant monitoring.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About H World Group Limited American Depositary Shares
H World Group operates hotels through leased and owned, managed franchise, and franchise models. Its brands include HanTing, JI Hotel, Orange Hotel, and Steigenberger Hotels & Resorts.
Read more on HTHT →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
